Cargando…

Synthesis, anti-bacterial evaluation, DFT study and molecular docking as a potential 3-chymotrypsin-like protease (3CLpro) of SARS-CoV-2 inhibitors of a novel Schiff bases

New Schiff bases {N'-(phenyl(pyridin-2-yl)methylene) isonicotinohydrazide (L(1)H), N(1)-(naphthalen-1-yl)-N(2)-(phenyl(pyridin-2-yl) methylidene) ethane-1,2-diamine (L(2)H), N-(6-chlorobenzo[d]thiazol-2-yl)-1-phenyl-1-(pyridin-2-yl) methanimine (L(3)H)}were synthesized by reaction of 2-benzoylp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Al-Janabi, Ahmed S.M., Elzupir, Amin O., Yousef, Tarek A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V. 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7568132/ https://www.ncbi.nlm.nih.gov/pubmed/33100378 http://dx.doi.org/10.1016/j.molstruc.2020.129454

Ejemplares similares

Biflavonoid as potential 3-chymotrypsin-like protease (3CLpro) inhibitor of SARS-Coronavirus
por: Hartini, Yustina, et al.
Publicado: (2021)

Molecular Docking and Dynamics Investigations for Identifying Potential Inhibitors of the 3-Chymotrypsin-like Protease of SARS-CoV-2: Repurposing of Approved Pyrimidonic Pharmaceuticals for COVID-19 Treatment
por: Elzupir, Amin Osman
Publicado: (2021)

Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents
por: Mody, Vicky, et al.
Publicado: (2021)

Biochemical and biophysical characterization of the main protease, 3-chymotrypsin-like protease (3CLpro) from the novel coronavirus SARS-CoV 2
por: Ferreira, Juliana C., et al.
Publicado: (2020)

Molecular Docking Analysis of Anti-Severe Acute Respiratory Syndrome-Coronavirus 2 Ligands against Spike Glycoprotein and the 3-Chymotrypsin-Like Protease
por: Janabi, Ali Hassan Daghir
Publicado: (2021)

Computer-Aided Screening for Potential Coronavirus 3-Chymotrypsin-like Protease (3CLpro) Inhibitory Peptides from Putative Hemp Seed Trypsinized Peptidome
por: Prasertsuk, Kansate, et al.
Publicado: (2022)

pH profiles of 3-chymotrypsin-like protease (3CLpro) from SARS-CoV-2 elucidate its catalytic mechanism and a histidine residue critical for activity
por: Al Adem, Kenana, et al.
Publicado: (2022)

Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach
por: Molavi, Zahra, et al.
Publicado: (2021)

Inhibition of SARS-CoV-2 main protease 3CL(pro) by means of α-ketoamide and pyridone-containing pharmaceuticals using in silico molecular docking
por: Elzupir, Amin O.
Publicado: (2020)

Docking and Electronic Structure of Rutin, Myricetin, and Baicalein Targeting 3CLpro
por: Farias, Sergio A. de S., et al.
Publicado: (2023)

Discovery of 3CLpro inhibitor of SARS-CoV-2 main protease
por: Kuang, Yi, et al.
Publicado: (2023)

Trypsin- and Chymotrypsin-Like Serine Proteases in Schistosoma mansoni – ‘The Undiscovered Country’
por: Horn, Martin, et al.
Publicado: (2014)

Loss of chymotrypsin-like protease (CTRL) alters intrapancreatic protease activation but not pancreatitis severity in mice
por: Mosztbacher, Dóra, et al.
Publicado: (2020)

Pharmacoinformatic study of inhibitory potentials of selected flavonoids against papain-like protease and 3-chymotrypsin-like protease of SARS-CoV-2
por: Tijjani, Habibu, et al.
Publicado: (2022)

Multistep rational molecular design and combined docking for discovery of novel classes of inhibitors of SARS-CoV-2 main protease 3CLpro
por: Tumskiy, Roman S., et al.
Publicado: (2021)

Ginkgolic acid and anacardic acid are reversible inhibitors of SARS-CoV-2 3-chymotrypsin-like protease
por: Li, Dongsheng, et al.
Publicado: (2022)

Structurally- and dynamically-driven allostery of the chymotrypsin-like proteases of SARS, Dengue and Zika viruses
por: Lim, Liangzhong, et al.
Publicado: (2019)

Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection
por: Vandyck, Koen, et al.
Publicado: (2021)

Exploration of chalcones as 3-chymotrypsin-like protease (3CL(pro)) inhibitors of SARS-CoV-2 using computational approaches
por: Lam, Thua-Phong, et al.
Publicado: (2022)

New 1,2,3-Triazole Scaffold Schiff Bases as Potential Anti-COVID-19: Design, Synthesis, DFT-Molecular Docking, and Cytotoxicity Aspects
por: Said, Musa A., et al.
Publicado: (2021)

Assessment of activity of chalcone compounds as inhibitors of 3-chymotrypsin like protease (3CL(Pro)) of SARS-CoV-2: in silico study
por: Mathpal, Shalini, et al.
Publicado: (2022)

Treponema denticola chymotrypsin-like protease as associated with HPV-negative oropharyngeal squamous cell carcinoma
por: Kylmä, Anna Kaisa, et al.
Publicado: (2018)

GC-MS, LC-MS/MS, Docking and Molecular Dynamics Approaches to Identify Potential SARS-CoV-2 3-Chymotrypsin-Like Protease Inhibitors from Zingiber officinale Roscoe
por: Zubair, Muhammad Sulaiman, et al.
Publicado: (2021)

Dual inhibition of COVID-19 spike glycoprotein and main protease 3CLpro by Withanone from Withania somnifera
por: Patil, Vishal Shivalingappa, et al.
Publicado: (2021)

A Study of Drug Repurposing to Identify SARS-CoV-2 Main Protease (3CLpro) Inhibitors
por: Jo, Seri, et al.
Publicado: (2022)

The main protease 3CLpro of the SARS-CoV-2 virus: how to turn an enemy into a helper
por: Belenkaya, Svetlana V., et al.
Publicado: (2023)

Identification of novel drug scaffolds for inhibition of SARS-CoV 3-Chymotrypsin-like protease using virtual and high-throughput screenings
por: Lee, Hyun, et al.
Publicado: (2014)

Structure and Cleavage Specificity of the Chymotrypsin-Like Serine Protease (3CLSP/nsp4) of Porcine Reproductive and Respiratory Syndrome Virus (PRRSV)
por: Tian, Xinsheng, et al.
Publicado: (2009)

Synthesis, characterization, DFT analysis and docking studies of a novel Schiff base using 5-bromo salicylaldehyde and β-alanine
por: Meenukutty, M.S., et al.
Publicado: (2022)

3CLpro inhibitors: DEL-based molecular generation
por: Xiong, Feng, et al.
Publicado: (2022)

Structural comparison strengthens the higher-order classification of proteases related to chymotrypsin
por: Mönttinen, Heli A. M., et al.
Publicado: (2019)

Synthesis, Crystal Structure, DFT Studies and Evaluation of the Antioxidant Activity of 3,4-Dimethoxybenzenamine Schiff Bases
por: Aziz, Ahmad Nazif, et al.
Publicado: (2014)

AN ENZYME IN MAST CELLS WITH PROPERTIES LIKE CHYMOTRYPSIN
por: Benditt, Earl P., et al.
Publicado: (1959)

Dimethyl sulfoxide reduces the stability but enhances catalytic activity of the main SARS‐CoV‐2 protease 3CLpro
por: Ferreira, Juliana C., et al.
Publicado: (2021)

Key dimer interface residues impact the catalytic activity of 3CLpro, the main protease of SARS-CoV-2
por: Ferreira, Juliana C., et al.
Publicado: (2022)

Corrigendum: The main protease 3CLpro of the SARS-CoV-2 virus: how to turn an enemy into a helper
por: Belenkaya, Svetlana V., et al.
Publicado: (2023)

In silico analysis and identification of antiviral coumarin derivatives against 3-chymotrypsin-like main protease of the novel coronavirus SARS-CoV-2
por: Abdizadeh, Rahman, et al.
Publicado: (2021)

Cloning a Chymotrypsin-Like 1 (CTRL-1) Protease cDNA from the Jellyfish Nemopilema nomurai
por: Heo, Yunwi, et al.
Publicado: (2016)

Molecular Recognition of Chymotrypsin by the Serine Protease Inhibitor Ecotin from Yersinia pestis
por: Clark, Elizabeth A., et al.
Publicado: (2011)

Catalytic Dyad Residues His41 and Cys145 Impact the Catalytic Activity and Overall Conformational Fold of the Main SARS-CoV-2 Protease 3-Chymotrypsin-Like Protease
por: Ferreira, Juliana C., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_njc5qep0shmkvi6163tjjed468